JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 1989; 13:19-26
© 1989 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Magnani, B
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Magnani, B

Plasminogen Activator Italian Multicenter Study (PAIMS): comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction

B Magnani

Istituto di Malattie Cardiovascolari dell'Universita, Ospedale Policlinico S. Orsola, Bologna, Italy.

A single chain preparation of recombinant tissue-type plasminogen activator (rt-PA) was compared with intravenous streptokinase to determine coronary thrombolytic efficacy in patients with acute myocardial infarction less than 3 h old. Eighty-six patients were randomly selected to receive the intravenous cumulative dose of 100 mg rt-PA and 85 patients to receive 1.5 million units streptokinase. At 240 min after initiation of the thrombolytic therapy noninvasive signs of sustained reperfusion occurred in 79% of patients in both groups (p = NS). Patency of the infarct-related vessel at follow-up angiography was observed in 81% of patients in the rt-PA group and 74% of patients in the streptokinase group (p = NS). At hospital discharge, compared with admission, echocardiographically determined left ventricular ejection fraction increased from 52 +/- 11% to 56 +/- 10% (p less than 0.01) in the rt-PA group; changes in the streptokinase group (50 +/- 9% to 51 +/- 11%) were not significant. A nadir value of less than 1 g/liter fibrinogen plasma level occurred in 6 patients (7%) receiving rt-PA versus 74 patients (87%) receiving streptokinase (p less than 0.0001). Plasma levels of fibrin(ogen) degradation products were more than doubled in the streptokinase group (p less than 0.01). One patient in the streptokinase group developed a fatal intracranial hemorrhage; five others showed a decline in hemoglobin greater than or equal to 5 g/dl. Other clinical events in the streptokinase-treated group included allergic reactions (four patients) and intrahospital reinfarction (two patients). None of these events occurred in the rt-PA group.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
 QJMHome page
Y. Dundar, R. Hill, R. Dickson, and T. Walley
Comparative efficacy of thrombolytics in acute myocardial infarction: a systematic review
QJM, February 1, 2003; 96(2): 103 - 113.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
E. M. Ohman, R. A. Harrington, C. P. Cannon, G. Agnelli, J. A. Cairns, and J.W. Kennedy
Intravenous Thrombolysis in Acute Myocardial Infarction
Chest, January 1, 2001; 119(1_suppl): 253S - 277S.
[Full Text] [PDF]

Home page
 CirculationHome page
C. R. Benedict, C. J. Refino, B. A. Keyt, R. Pakala, N. F. Paoni, G. R. Thomas, and W. F. Bennett
New Variant of Human Tissue Plasminogen Activator (TPA) With Enhanced Efficacy and Lower Incidence of Bleeding Compared With Recombinant Human TPA
Circulation, November 15, 1995; 92(10): 3032 - 3040.
[Abstract] [Full Text]

Home page
 Journal of Pharmacy PracticeHome page
D. W. Krichbaum and D. A. Trivedi
Thrombolytic Therapy in Acute Myocardial Infarction
Journal of Pharmacy Practice, January 1, 1990; 3(5): 332 - 348.
[PDF]


HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1989 by the American College of Cardiology Foundation.